Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
Tetraethylammonium Chloride: Precision Tools for Vascular an
2026-06-03
Explore the multifaceted role of Tetraethylammonium chloride (TEAC) as a dual-site potassium channel blocker in vascular and metabolic research. This article uncovers advanced mechanistic insights and practical workflows for leveraging TEAC in translational physiology—distinct from prior scenario-focused content.
-
Nicotinamide Adenine Dinucleotide (NAD+): Applied Workflow A
2026-06-03
Nicotinamide Adenine Dinucleotide (NAD+) is pivotal for dissecting metabolic signaling, autophagy, and DNA repair. This guide spotlights experimental enhancements, troubleshooting, and translational insights, leveraging APExBIO’s high-purity NAD+ for robust, reproducible results in stress adaptation research.
-
Refining In Vitro Drug Response Evaluation in Cancer Researc
2026-06-02
Schwartz's dissertation introduces a nuanced approach to measuring anti-cancer drug effects in vitro, distinguishing between growth inhibition and cell death. This methodological clarity enhances interpretation of drug efficacy, informing both preclinical research and translational oncology.
-
Gemcitabine HCl and Multianimal MRI: Transforming Pancreatic
2026-06-02
Explore how the mechanistic power of Gemcitabine HCl, a deoxycytidine analog, can be strategically leveraged in translational pancreatic cancer research. This article blends deep molecular insight with advanced MRI-guided workflows and offers actionable guidance for accelerating preclinical development using validated, high-throughput imaging and cytotoxicity protocols.
-
Deep Learning Enhances Cardiotoxicity Detection in iPSC-CMs
2026-06-01
This study demonstrates how deep learning applied to high-content imaging of induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) enables rapid, scalable detection of drug-induced cardiotoxicity. The approach improves early-stage screening, informing safer drug development and providing a robust phenotypic platform for cardiac arrhythmia research.
-
ABT-737: Beyond Oncology—Targeting Senescent Cells via BCL-2
2026-06-01
Explore ABT-737, a potent BCL-2 protein inhibitor, and its unique role in selectively eliminating senescent cells beyond traditional cancer models. Discover how new findings in type 1 diabetes research expand the scope of apoptosis induction and offer innovative research pathways.
-
AGO1 Facilitates Protein Folding to Maintain Embryonic Stemn
2026-05-31
Liu et al. reveal that AGO1 promotes the maintenance of pluripotency in mouse embryonic stem cells by facilitating protein folding, independently of small RNA binding. This discovery uncovers a previously unrecognized, RNA-independent role for AGO1 in cell fate regulation, which has significant implications for stem cell biology and experimental design.
-
Spermine tetrahydrochloride: Mechanisms, Benchmarks, and Pro
2026-05-30
Spermine tetrahydrochloride is a polyamine stabilizer and modulator widely used in membrane, protein, and NMDA receptor studies. It supports reproducible results in protoplast protection, protein crystallization, and polyphosphazene nanoparticle workflows. APExBIO’s B6522 product offers high-purity, water-soluble spermine tetrahydrochloride with robust experimental utility.
-
Disabling Tumor Extracellular Vesicles to Inhibit Metastasis
2026-05-29
This study introduces a lipidated nanophotosensitizer capable of tracing and disabling tumor extracellular vesicles (TEVs), offering a dual approach to suppress both tumor growth and metastasis. The work demonstrates that targeted photodynamic therapy can impede TEV-mediated communication, addressing a major bottleneck in current metastatic cancer treatments.
-
Cy5 NHS ester(Et): Technical Guidance for Fluorescent Labeli
2026-05-29
Cy5 NHS ester(Et) enables efficient, water-soluble fluorescent labeling of primary amines in proteins and biomolecules for detection workflows in immunofluorescence, flow cytometry, and fluorescence microscopy. It is unsuitable for ethanol-based protocols and should not be stored in solution for extended periods. This article outlines practical use, limitations, and troubleshooting for optimal results.
-
Gemcitabine: Applied Workflows and Troubleshooting in Cancer
2026-05-28
Gemcitabine, a potent DNA synthesis inhibitor, is pivotal for dissecting DNA damage responses and apoptosis in cancer models. This article presents stepwise protocol enhancements, experimental caveats, and troubleshooting tips that maximize Gemcitabine’s value in translational oncology, informed by recent metabolic insights and robust performance benchmarks.
-
Sabutoclax as a Pan-Bcl-2 Inhibitor: Systems Biology Insight
2026-05-28
Explore how Sabutoclax, a potent pan-Bcl-2 inhibitor, enables systems-level insights into apoptosis induction in cancer cells. This article uniquely integrates quantitative drug response frameworks and practical assay choices, advancing both experimental design and translational oncology.
-
Grazoprevir/Elbasvir: Redefining HCV Genotype 1 & 4 Therapy
2026-05-27
This review assesses the clinical impact of the fixed-dose combination of grazoprevir (MK-5172 hydrate) and elbasvir for hepatitis C virus (HCV) infection, especially genotypes 1 and 4. The study highlights the regimen’s high efficacy, broad patient applicability—including coinfection and renal impairment—and advances in tolerability and treatment simplicity.
-
VE-822 ATR Inhibitor: Enhancing Chemoradiotherapy in PDAC Mo
2026-05-27
VE-822, a highly potent ATR inhibitor, is redefining DNA damage response research and radiosensitization in pancreatic ductal adenocarcinoma (PDAC). This article details robust experimental workflows, practical troubleshooting, and emerging use-cases—especially where iPSC-based platforms guide drug selection in ultrarare contexts.
-
VE-822 ATR Inhibitor: Precision Tools for DDR Assay Innovati
2026-05-26
Explore how VE-822, a potent ATR inhibitor, is transforming DNA damage response (DDR) assay development and personalized cancer research. This in-depth review reveals advanced methodological insights and practical assay recommendations beyond existing protocol guides.